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Leukocyte telomere length (LTL) is a heritable biomarker of genomic aging. In this study, we perform a genome-wide meta-analysis of
LTL by pooling densely genotyped and imputed association results across large-scale European-descent studies including up to 78,592
individuals. We identify 49 genomic regions at a false dicovery rate (FDR) < 0.05 threshold and prioritize genes at 31, with five high-
lighting nucleotide metabolism as an important regulator of LTL. We report six genome-wide significant loci in or near SENP7,
MOB1B, CARMIL1, PRRC2A, TERF2, and RFWD3, and our results support recently identified PARP1, POT1, ATM, and MPHOSPH6 loci.
Phenome-wide analyses in >350,000 UK Biobank participants suggest that genetically shorter telomere length increases the risk of hy-
pothyroidism and decreases the risk of thyroid cancer, lymphoma, and a range of proliferative conditions. Our results replicate previ-
ously reported associations with increased risk of coronary artery disease and lower risk for multiple cancer types. Our findings substan-
tially expand current knowledge on genes that regulate LTL and their impact on human health and disease.Introduction
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disease (CAD) and some cancers.7–12 However, whether
LTL (reflecting TL across tissues) was causally associated
with disease or whether the observed associations may
have been due to reverse causation or confounding was
unclear.
LTL is both variable among individuals, from birth and
throughout the life course, and highly heritable, with
heritability estimates from 44%–86%.13,14 Identification
of genetic determinants of LTL through a genome-wide
association study (GWAS) has allowed further studies to
suggest a causal role for LTL in several diseases, including
CAD, abdominal aortic aneurysm, several cancers, intersti-
tial lung disease, and celiac disease.15–19 However, these
studies are limited due to the small number of genetic
variants that have been identified that replicate between
studies.15,20–25 To further our understanding of LTL
regulation and its relationship with disease, we have con-
ducted a genome-wide association (GWA) meta-analysis
of 78,592 individuals from the European Network for Ge-
netic and Genomic Epidemiology (ENGAGE) study and
from the European Prospective Investigation into Cancer
and Nutrition (EPIC) Cardiovascular Disease (CVD) and
InterAct studies.Subjects and Methods
Full descriptions of the EPIC-CVD and EPIC-InterAct cohorts,
along with the participating cohorts within the ENGAGE con-
sortium, are given in the Supplemental Information.
LTL Measurements and QC Analysis
Mean LTL measurements were conducted using an established
quantitative PCR technique which expressed TL as a ratio of the
telomere repeat number (T) to a single-copy gene (S).26,27 The
majority of the ENGAGE samples were included within our previ-
ous analysis.15 LTL measurements were standardized either by
using a calibrator sample or by quantifying against a standard
curve, depending on the laboratory (Table S1 and Supplemental
Methods). Full details of the methodology employed by each lab-
oratory, along with quality control (QC) parameters, is given in
the Supplemental Information or is given in detail elsewhere.15
Because the use of different calibrator samples or of standard
curves for quantification can lead to different ranges in the T/S ra-
tios being observed between laboratories, we standardized LTL by
using a z-transformation approach (z ¼ (m - m0)/s, m, T/S ratio, m0,
the mean T/S ratio, s, standard deviation [SD]).
Genotyping, GWAS Analysis, and Study-Level QC
Genotyping platforms and imputationmethods and panels varied
across participating study centers. Detailed information about
these is provided in Figure S1 and Table S2. A GWAS was run
within each study through the use of linear regression under an
additive mode of inheritance with adjustment for age, sex, and
any study-specific covariates, including batch, center, and genetic
principle components. There are 21 studies contributing to
ENGAGE. For the EPIC InterAct and CVD studies, association an-
alyses were stratified based on genotyping platform and disease
status, resulting in nine strata. Within each study or stratum,
related samples (k > 0.088) were removed. Population stratifica-The Amerition was estimated using the genomic control inflation factor l
and used to adjust the standard errors. Genetic variants were
filtered on the basis of the published standards that included call
rate >95%, Hardy–Weinberg equilibrium p < 1 3 106, imputa-
tion quality info-score >0.4 or R2 > 0.3, minor allele count S10,
and standard error of association estimates ranging from 0 to
10.15,28,29 These data were taken forward to the meta-analysis.Meta-analyses
GWAS summary statistics were combined via two steps of meta-
analyses by using inverse variance weighting in GWAMA.30 We
first combined all 21 ENGAGE studies together and separately
combined the nine EPIC-InterAct and EPIC-CVD strata, where a
genetic variant was retained if it had>40% of the available sample
size within these two cohorts. Fixed effects were used except
for variants with significant heterogeneity (Cochrane’s Q: p <
1 3 106), in which case random effects were used. Additional
adjustment was made for genomic inflation (see Figure S2). In
the second step, association estimates derived from the two sepa-
rate meta-analyses estimated in the first step were combined using
fixed effects inverse variance weighted meta-analyses. We esti-
mated the FDR by estimating q-values31 for these data.Conditional Association Analysis
Conditionally independent signals were identified via an approx-
imate genome-wide stepwise method, using GCTA (Version
1.25.2),32,33 that allows for conditional analyses to be run on sum-
mary statistics without individual-level data. Summary statistics
from the final meta-analysis were used as the input, with p value
cut-offs at 5 3 108 (genome-wide significance) or 1.03 3 105
(equivalent to an FDR < 0.05). The model starts with the most sig-
nificant SNP, adds in SNPs iteratively in a forward stepwise
manner, and calculates conditional p values for all SNPs within
the model. If the target SNP shows evidence of collinearity (corre-
lation coefficients r2 > 0.9, with linkage disequilibrium (LD) esti-
mated based on a random subcohort of 50,000 UK Biobank sam-
ples) with any of the SNPs selected into the model, the
conditional p value of the target SNP was set to 1. The selection
process was repeated until no more SNPs could be fitted into the
model, i.e., there were no more SNPs that could reach the condi-
tional p value thresholds (53 108 or 1.033 105, corresponding
to the p value cut-offs in the input). Joint effects of all selected
SNPs that fitted in the model were calculated and reported as inde-
pendent variants’ effects. Regional plots of a 1Mb window flank-
ing the locus sentinel variants (p< 53 108) were generated using
LocusZoom34 with LD structure estimated in the UK Biobank sub-
cohort (see Figure S3).Gene Prioritization
Variant Annotation
Sentinel variants (conditional p < 1.03 3 105) and their proxies
(r2 < 0.8) were annotated on the human reference genome
sequence hg19 using Annovar (v2017July16).35 Their functional
consequences on the protein sequences encoded by the nearest
genes were cross-validated using definitions from RefGene,36 En-
sembl gene annotation,37 GENCODE,38 and the University of
California, Santa Cruz (UCSC) human genome database.39 These
variants were also evaluated for features including evolutionary
conservation (whether they reside in or specifically encode
an conserved element based on multiple alignments across 46
vertebrate species), chromatin states predicted using Hiddencan Journal of Human Genetics 106, 389–404, March 5, 2020 391
Markov Models trained by CHIP-seq data from ENCODE (15 clas-
sified states across nine cell types), histone modification markers
(active promoter: H3K4Me3, H3K9Ac; active enhancer:
H3K4me1, H3K27Ac; active elongation: H3K36me3; and repressed
promoters and broad regions: H3K27me3), and CTCF transcrip-
tion factor binding sites across nine cell lines, conserved putative
TFBS, and DNaseI hypersensitive areas curated from the ENCODE
database.38 Variants within the exonic regions were further anno-
tated with allele frequencies in seven ethnical groups (retrieved
from the Exome Aggregation Consortium database) and func-
tional effects prediction performed using a number of different al-
gorithms. For non-coding variants, we performed integrated anal-
ysis with SNP Nexus IW scoring.40
Transcriptomic Data Integration
(1) With summary statistics, we performed a gene-level analysis,
using S-PrediXcan, that links LTL to predicted gene expressions
across 44 tissues (GTex v6p). It uses multivariate sparse regression
models that integrate cis-SNPs within 2Mb windows around gene
transcript boundaries in order to predict the corresponding gene
expression levels. A detailed description of the method can be
found elsewhere.41,42 In brief, individual SNP-LTL associations
were weighted by SNP-gene (wlg) and SNP-SNP ðsl =sgÞ association
matrix, estimated from the PredictDB training set (zg ¼
P
l˛g
wlg ðsl =sgÞ zl, for a gene (g); the set of SNPs (l) were selected
from an elastic net model with a mixing parameter of 0.5). Pro-
tein-coding genes with qualified prediction model performance
(average Pearson’s correlation coefficients r2 between predicted
and observed gene expressions >0.01, FDR < 0.05) were included
in our analysis. We considered a predicted gene expression to be
significantly associated with LTL at a Bonferroni corrected p value
threshold (p < 2.61 3 107), conservatively assuming association
of each gene in each tissue as an independent test.
(2) For a given region significantly associated with LTL (FDR <
0.05), we tested whether the potential causal variants are shared
between LTL and gene expressions by using COLOC Bayesian
approach.43 Regions for testing were determined as 2Mb win-
dows surrounding the sentinel variants. Regional summary sta-
tistics were extracted from this GWA meta-analysis for associa-
tions with LTL and GTex v744 for cis-eGenes (genes with
significant expression quantitative trait loci [eQTLs], FDR <
0.05) located within or on the boundaries of LTL regions
defined. We selected the default priors for this analysis. We set
p1 ¼ p2 ¼ 104, meaning that 1 in 10,000 variants is associated
with either trait (LTL or gene expression), as has been suggested
by others.43 We set p12 ¼ 105, meaning that 1 in 10 (p12/
(p12 þ p1)) variants that are associated with one trait is also
associated with the other. This was chosen because sensitivity
analyses have shown broadly consistent results between this
setting and more stringent (p12 ¼ 105) settings, while allowing
greater power.45 Evidence for colocalization was assessed by
comparing the posterior probability (PP) for two hypotheses:
that the associations for both traits were driven by the same
causal variants (hypothesis 4) and that they were driven by
distinct ones (hypothesis 3). Strong evidence of a co-localized
eQTL was defined as PP3 þ PP4 R 0.99 and PP4/PP3 R 5, and
suggestive evidence was defined as PP3 þ PP4 R 0.90 and
PP4/PP3 R 3, consistent with previous studies.46,47
Epigenomic (DNA Methylation) Data Integration
For genes whose expressions are modulated by epigenetic modifi-
cations, such as the methylation of transcriptional regulators in
cis, linking genetic variants associated with cis-methylation probes392 The American Journal of Human Genetics 106, 389–404, March(cis-meQTLs, FDR < 0.05) to LTL can help gene prioritization. For
this: (1) We conducted a systematic search of LTL-associated
sentinel variants and their proxies (r2 > 0.8) in multiple publicly
available meQTL databases.48–50 (2) We also performed an epige-
nome-wide association analysis that integrated multiple variants’
associations in a regularized linear regression model which was
algorithmically similar to the transcriptome-wide association ana-
lyses.51 A reference panel formeQTLs was constructed based on in-
dividuals in the EPIC-Norfolk cohort, with detailed description
published elsewhere.52 Bonferroni correction was applied, ac-
counting for the total number of CpG markers tested (p ¼
1.00 3 107).
Pathway Enrichment Analysis
Using two different approaches, we sought to identify pathways
that are responsible for regulating TL.
PANTHER
A list of our prioritized genes at each locus (or the nearest gene
where no prioritization was possible) was submitted for statistical
overrepresentation testing (Fisher’s exact test) in Protein Analysis
through Evolutionary Relationships (PANTHER).53 Pathways
(Gene Ontology [GO] molecular function complete annotation
dataset) were considered over-represented where FDR p < 0.05.
DEPICT
We also used a hypothesis-free, data-driven approach using
Data-driven Expression Prioritized Integration for Complex Traits
(DEPICT)54 to highlight reconstituted gene sets and tissue and/or
cell types where LTL-associated loci were enriched. Summary sta-
tistics of uncorrelated SNPs (LD r2 & 0.5) significantly associated
with LTL at a genome-wide level (p < 5 3 108) were used as
the input, and the HLA region (chr6:29691116–33054976) was
excluded. DEPICT first defined each locus around the uncorrelated
variants and selected the genes within the region. It then charac-
terized gene functions based on pairwise co-regulation of gene
expressions, and these gene functions were quantified as member-
ship probabilities across the 14,461 reconstituted gene sets. Then
for each gene set, it assessed the enrichment by testing whether
the sum of membership scores of all genes within each LTL-associ-
ated locus was higher than that for a gene-density-matched
random locus. Detailed description of gene set construction was
published elsewhere.54 In brief, DEPICT leveraged a broad range
of pre-defined pathway-oriented databases to construct gene
sets (14,461), including GO terms,55 KEGG,56 REACTOME path-
ways,57 the experimentally derived protein-protein interaction
(PPI) subnetwork,58 and the gene-phenotype matrix curated by
Mouse Genetics Initiative.59 Correlations (rS 0.3) between signif-
icant gene sets were visualized using CytoScape.60
Clinical Relevance of LTL
Mendelian Randomization
Using two-sample Mendelian randomization (MR)61 we investi-
gated the potential effect of LTL on 122 diseases manually curated
in the UK Biobank (Table S3).62 Diseases were selected where there
were sufficient case numbers to detect an odds ratio >1.1 (Table
S4). LTL was genetically proxied based on 52 independently asso-
ciated variants (FDR < 0.05). Individual SNP effects on disease
were tested using logistic regression in SNPTEST,63 adjusting for
sex, age, the first five genetic principal components, and genotyp-
ing array within the UK Biobank. MR estimates were calculated
using an inverse variance weighted MR approach. Sensitivity
analyses were performed using median-based MR,64 MR-RAPS,655, 2020
MR-Eggers,66 and MR-Steigers67 to identify inconsistency in the
MR estimates, account for weak instrument bias, highlight any
evidence of directional pleiotropy, and estimate direction of the
MR relationship, repectively.
LD Score Regression
Cross-trait linkage disequilibrium score regression (LDSC) anal-
ysis was used to measure genetic correlations between LTL and
selected traits through the use of the LD Hub database (version
1.4.1).68 From the 832 available traits in LD Hub, we a priori
selected traits of interest in order to remove redundancy and/or
duplication within the analysis. We removed poorly defined
traits and diseases, those without prior evidence of a genetic ba-
sis, and medications. We also removed lipid sub-fractions
because we thought these unlikely to be relevant. We excluded
studies with a sample size <1,000. Where multiple datasets for
the same trait existed, we first prioritized datasets from large
specialist consortia (where relevant factors would have been
accounted for within the GWAS analysis) over the UK Biobank
analyses conducted by the Neale group (where the GWAS was
acknowledged to be a ‘‘quick and dirty’’ analysis). We then
prioritized larger sample size, more recent studies, and diagnosed
conditions over self-reported ones. We also removed traits with
low heritability estimates within LD Hub, leaving us with 320
traits (information, including PMIDs of the selected studies, is
given in the Results section).
Genome-wide summary statistics were used as the input,
and standardized quality control was implemented within
the software, including minor allele frequency (MAF) (>1%
for HapMap3 and >5% for 1000 Genomes EUR-imputed
SNPs), effective sample size (>0.67 times the 90th percentile of
sample size), removal of insertions or deletions or structural
variants, allelic alignment to 1000 Genomes, and removal of
SNPs within the major histocompatibility complex (MHC)
region.
Variants-based Cross-database Query
Independent variants and their strong proxies (r2 R 0.8) were
queried against publicly available GWAS databases; for this, we
used PhenoScanner69 for computational efficiency. A list of
GWAS results implemented in the software was previously pub-
lished. Results were filtered to include associations with p < 1 3
106, in high LD (r2>0.8) with the most significant SNPs within
the region, and manually curated to retain only the most recent
and largest study per trait.Results
Discovery of Genetic Determinants of LTL
Mean LTL was measured within each cohort by using a
quantitative polymerase chain reaction (qPCR)-based
method, which expresses TL as a ratio of telomere repeat
content (T) to single-copy gene (S) within each sample
(see Subjects and Methods, Supplemental Information,
and Table S1). T/S ratios were z-standardized to harmo-
nize differences in the quantification and calibration pro-
tocols between cohorts. Associations of shorter LTL with
increasing age and male gender were observed as expected
(Table S1).
Variants were assessed for association with mean LTL
within each cohort through the use of additive models
adjusted for age, gender, and cohort-specific covariatesThe Ameriand then combined using inverse-variance-weighted
meta-analysis (Table S2).
In total, 20 sentinel variants at 17 genomic loci were
independently associated with LTL at a level of genome-
wide statistical significance (p < 5 3 108, Table 1,
Figure S1), including six loci that had not previously been
associated with LTL (SENP7 [MIM: 612846], MOB1B
[MIM:609282], CARMIL1 [MIM: 609593], PRRC2A [MIM:
142580], TERF2, and RFWD3 [MIM: 614151]). We also
identified genome-wide significant variants in four recently
reported loci from a Singaporean Chinese population
(POT1, PARP1 [MIM: 173870], ATM [MIM:607585], and
MPHOSPH6 [MIM:605500])70 and confirmed association
at seven previously reported loci in European ancestry
studies (TERC, NAF1 [MIM: 617868], TERT, STN1(OBFC1),
DCAF4 [MIM: 616372], ZNF208 [MIM: 603977], and
RTEL1).15,23 Two and three conditionally independent sig-
nals were detected within the TERT and RTEL1 loci, respec-
tively (Table 1). Within the known loci, three variants
within the DCAF4 (r2 ¼ 0.05) and TERT (r2 < 0.5) loci
were distinct from the previously reported sentinel variants,
while five (TERC, NAF1, STN1, ZNF208, and RTEL1; r2 >
0.8; Table S5) were in high LD with the previously reported
ones from European studies. For the loci identified in a
Chinese ancestry population, we observed the same
sentinel variant for PARP1 and high LD variants for ATM
and MPHOSPH6 (r2 > 0.8) but a distinct sentinel for POT1
(r2 < 0.5, Table S5). While we observed a distinct sentinel
for POT1, we cannot rule out the possibility that the associ-
ation signal observed in this region could be shared. In that
case, the sentinels identified in each population would be
reflective of a third, as yet unidentified, variant that is the
true causal variant in this region. For the RTEL1 locus, there
are significant differences in LD structure between ancestral
populations. All of the RTEL1 variants we report at genome-
wide statistical significance are in low LD with those re-
ported in Singaporean Chinese and in South Asians.25,70
Our novel variants are of lower frequency (MAF < 0.1)
and either are reported as being monoallelic (monomor-
phic) or fall below the MAF threshold for analysis in the
Southern Han Chinese (CHS) population (MAF < 0.01).
This suggests that genetic variation in this region may be,
in part, population specific or that the MAF is so low that
we currently are unable to detect any association.
It has been shown that many loci that fall just below the
conventional threshold of genome-wide significance are
genuinely associated with the trait of interest and do
subsequently reach the conventional threshold when sam-
ple size is increased.71 In an attempt to gain additional
insight into the genetic determination of LTL in humans,
we applied a less stringent FDR threshold to the data. An
additional 32 variants met an FDR threshold of <0.05,
totaling 52 variants that estimate ~2.93% of the variance
in TL (Table S6).71 Within this FDR list, 5% of variants
(2–3) are estimated to be false positives, although we are
not able to determine which they are. While we believe
that this FDR is acceptable, we advise that individual locican Journal of Human Genetics 106, 389–404, March 5, 2020 393
Table 1. Independent Variants Associated with LTL at Genome-Wide Significance (5x108)
SNP Gene Chr Position (hg19) EA EAF Beta SE p Value
Previously Reported Loci
rs3219104 PARP1 1 226562621 C 0.83 0.042 0.006 9.60 3 1011
rs10936600 TERC 3 169514585 T 0.24 0.086 0.006 7.18 3 1051
rs4691895 NAF1 4 164048199 C 0.78 0.058 0.006 1.58 3 1021
rs7705526 TERT 5 1285974 A 0.33 0.082 0.006 5.34 3 1045
rs2853677* TERT 5 1287194 A 0.59 0.064 0.006 3.35 3 1031
rs59294613 POT1 7 124554267 A 0.29 0.041 0.006 1.17 3 1013
rs9419958 STN1 (OBFC1) 10 105675946 C 0.86 0.064 0.007 5.05 3 1019
rs228595 ATM 11 108105593 A 0.42 0.029 0.005 1.43 3 108
rs2302588 DCAF4 14 73404752 C 0.10 0.048 0.008 1.68 3 108
rs7194734 MPHOSPH6 16 82199980 T 0.78 0.037 0.006 6.94 3 1010
rs8105767 ZNF208 19 22215441 G 0.30 0.039 0.005 5.42 3 1013
rs75691080 RTEL1/STMN3 20 62269750 T 0.09 0.067 0.009 5.99 3 1014
rs34978822* RTEL1 20 62291599 G 0.02 0.140 0.023 7.26 3 1010
rs73624724* RTEL1/ZBTB46 20 62436398 C 0.13 0.051 0.007 6.33 3 1012
Additional Loci
rs55749605 SENP7 3 101232093 A 0.58 0.037 0.007 2.45 3 108
rs13137667 MOB1B 4 71774347 C 0.96 0.077 0.014 2.43 3 108
rs34991172 CARMIL1 6 25480328 G 0.07 0.061 0.011 6.19 3 109
rs2736176 PRRC2A 6 31587561 C 0.31 0.035 0.006 3.53 3 1010
rs3785074 TERF2 16 69406986 G 0.26 0.035 0.006 4.64 3 1010
rs62053580 RFWD3 16 74680074 G 0.17 0.039 0.007 4.08 3 108
Gene—the closest or candidate gene (known telomere-related function) within the region. EA—effect allele. EAF—effect allele frequency within the study. Beta—
the per-allele effect on z-scored LTL. SE—standard error.
*Additional, independent signals detected using conditional analysis are included.should be interpreted with some caution. These variants
were located within separate loci from those reported
above, with the exception of a fourth, independent signal
in the RTEL1 locus. Although we did not replicate the pre-
viously reported ACYP2 (MIM: 102595) locus, this did
remain within the variants identified at the FDR < 0.05
threshold. TYMS (MIM: 188350), identified as genome-
wide significant in a trans-ethnic meta-analysis of Singa-
porean Chinese67 and in the previously reported ENGAGE
analysis,15 is within our FDR < 0.05 identified loci. This
was to be expected considering the substantial sample
overlap of the ENGAGE data; however, our sentinel variant
is distinct and not reported in the Dorajoo et al. study.
Aligning our data with available summary statistics from
the Dorajoo et al. study (Singaporean Chinese samples
only), we see at least nominal support for the vast majority
of our genome-wide significant loci, with the exception of
STN1(OBFC1) and SENP7 (Table S7). Although SENP7 has
not previously been reported, variants in high LD (r2 >
0.6) with our STN1 sentinel have been reported in other
European populations.21,22 There is also support for394 The American Journal of Human Genetics 106, 389–404, Marchmany variants in our extended FDR list. However, it should
be noted that data are not available for around half of our
FDR < 0.05 loci, with most of these being either monoal-
lelic or too low frequency to have been included within
the analysis in the CHS population, again suggesting that
several may be specific to the European population.
Prioritization of Likely Candidate Genes
We applied in silico prediction tools, leveraging large-scale
human genomic data integrated with multi-tissue gene
expression, transcriptional regulation, and DNA methyl-
ation data, coupled with knowledge-driven manual cura-
tion, to prioritisze the genes that are most likely influenced
by the genetic variants within each locus. All 52 sentinel
variants identified at GWS and FDR < 0.05 (listed in Table
S6) plus their high LD proxies (r2 > 0.8) were taken forward
into our in silico analyses. First, we annotated all variants for
genomic location and location with respect to regulatory
chromatin marks (Tables S8 and S9). This also identified
variants that led to non-synonymous changes in nine
loci. Of these, five loci contained variants with predicted5, 2020
Figure 1. Loci with Established Roles in Telomere Biology
Candidate genes found in this study are shown in red. These include genes that encode components of the SHELTERIN complex (A),
regulate the formation and activity of telomerase (B), and regulate telomere structure (C).damaging effects on protein function (Table S10). We also
found evidence that variants were associated with changes
in gene expression in multiple loci (Table S11), with several
showing co-localization and evidence from two ap-
proaches. This data, along with prediction of functional
non-coding variants (Table S12), methylation QTL data
(Table S13), and curation of gene functions within the re-
gion (Supplemental Methods), are summarized in Table
S14. The summary data were utilized to prioritize genes
that are most likely influenced at each locus. Where the
prioritization methods suggested multiple genes for a given
locus, we prioritized based on the amount of evidence
across all considered lines of enquiry stated above. We
were able to prioritize genes at 15 of the 17 genome-wide
significant loci and 16 at of the 32 FDR loci (Table S14).
Four of the prioritized genes for newly identified loci
have known roles in telomere regulation (PARP1, POT1,
ATM, and TERF2; Figure 1). PARP1 (poly(ADP-ribose) poly-
merase 1), a variant in high LD (r2 ¼ 1.0) with our identi-
fied sentinel variant, causes a Val762Ala substitution (Table
S10) which is known to reduce PARP1 activity.72 This
variant was associated with shorter LTL, in agreement
with studies showing that knockdown of PARP1 leads to
telomere shortening.73 PARP1 catalyzes the poly(ADP-ribo-
syl)ation of proteins in several cellular pathways, including
DNA repair.73 It interacts with TERF2 and it regulates the
binding of TERF2 to telomeric DNA through this post-
translational modification.74
Three genes, DCAF4, SENP7, and RFWD3, prioritized
based on deleterious protein coding changes (DCAF4,The AmeriSENP7) or strong evidence linking to gene expression levels
(RFWD3), are all involved in DNA damage repair.75–77
SENP7 has previously been demonstrated to bind damaged
telomeres.78 Components of DNA damage response and
repair pathways (such as ATM) have been shown to also
play roles in telomere regulation.79 Mutations in RFWD3
cause Fanconi anemia (MIM: 617784), a disease linked to
telomere shortening and/or abnormalities.80
The PRRC2A locus contains 11 genetically linked SNPs
located across the MHC class III region, which is a highly
polymorphic and gene-dense region with complex LD
structure. BAG6 (MIM: 142590) and CSNK2B (MIM:
115441) were suggested as gene candidates for this region,
supported by gene expression data (see Supplemental In-
formation and Tables S11 and S14). BAG6 is linked to
DNA damage signaling and apoptosis,81 while CSNK2B, a
subunit of casein kinase 2, interacts with TERF1 and regu-
lates TERF1 binding at telomeres.82
Pathway Enrichment
To investigate context-specific functional connections
between prioritized genes of the identified loci and to
suggest plausible biological roles of these genes in the
TL regulation, we performed enrichment analyses for
pathways and tissues through the use of DEPICT54 and
PANTHER.53 DEPICT is a hypothesis-free, data-driven
approach for which we used summary statistics of all un-
correlated SNPs (LD r2 & 0.5) associated at p < 5 3 108
as input. For PANTHER, we assessed overrepresentation
of genes within our loci within known pathways. Tocan Journal of Human Genetics 106, 389–404, March 5, 2020 395
Figure 2. Pathways Enriched for Telomere-Associated Genes
(A) Gene sets significantly (false discovery rate [FDR] < 0.05) enriched for prioritised LTL-associated genes. Color intensity of the nodes
(gene sets), classified into three levels, reflects enrichment strengths (FDR). Edge width indicates Pearson correlation coefficient (r2) be-
tween each pair of the gene sets. Some of the most significantly associated gene sets include telomere maintenance along with DNA
replication and repair pathways as may be expected. How other enriched pathways may influence LTL is unclear.
(B) Role of LTL-associated genes in nucleotide metabolism. Five enzymatic reactions and genes encoding the corresponding enzymes
prioritized from this GWAS are highlighted in bold.minimize noise, we used our prioritized genes as input,
along with the closest gene to the sentinel SNP, where no
prioritization was possible. In total, 55 genes were submit-
ted to PANTHER, of which six were not available within
PANTHER, leaving 49 within the analysis.
Over 300 reconstituted gene sets (DEPICT) were signifi-
cantly enriched for the LTL loci (FDR < 0.05); these could396 The American Journal of Human Genetics 106, 389–404, Marchbe further clustered into 34 meta-gene sets, highlighting
pathways that are involved in several major cellular activ-
ities, including DNA replication, transcription, and repair;
cell cycle regulation; immune response; and intracellular
trafficking (Figure 2A).
The PANTHER analysis identified a number of telomere-
related pathways, including regulation of telomeric loop5, 2020
disassembly, t-circle formation, protein binding at telo-
meres, and single-strand break repair, as being the mostly
highly overrepresented (Table S15). Among other expected
pathways, cellular aging and senescence were also
highlighted. Of note, nucleotide metabolism pathways
were overrepresented (20-deoxyribonucleotide metabolic
process, deoxyribose phosphate metabolic process, and
deoxyribonucleotide metabolic process; Figure 2B; Table
S15). The genes matched to these pathways were TYMS,
SAMHD1 (MIM: 606754), and SMUG1 (MIM: 607753).
While TYMS is critical for deoxythymidine monophos-
phate (dTMP) biosynthesis, SAMHD1 controls deoxynu-
cloeside triphosphate (dNTP) catabolism and SMUG1 re-
moves misincorporated uracil from DNA.83–85 Although
not highlighted in the pathway analysis, two further genes
within other identified loci (TK1 [MIM: 188300] and DCK
[MIM:125450]) are key regulators of deoxynucleoside
monophosphate (dNMP) biosynthesis;85 this adds further
support to the possibility that nucleotide metabolism is a
key pathway in regulating LTL. dNTPs constitute the
fundamental building blocks required for DNA replication
and repair.86 Genetic perturbations that disrupt dNTP
homeostasis have been shown to result in increased repli-
cation error, cell cycle arrest, and DNA-damage-induced
apoptosis.85,87
Relationship between Genetically Determined TL and
Disease
To further understand the clinical relevance of TL, we used
the 52 independent variants identified at FDR< 0.05 as ge-
netic instruments for TL, and we applied a two-sample MR
approach using UK Biobank data.62 We manually curated
122 diseases available in the UK Biobank and examined
their relationships with shorter TL (Tables S3 and S16).
We observed nine associations which passed a Bonferroni
corrected threshold (p < 4.1x104). These included novel
findings of an increased risk of hypothyroidism, and
decreased risk of thyroid cancer, lymphoma, and diseases
of excessive growth (uterine fibroids, uterine polyps, and
benign prostatic hyperplasia). We also confirmed findings
for decreased risk of lung and skin cancer and leukemia
for subjects with shorter TL (Figure 3, Table S16).16,18,88
We observed a further 30 nominally significant associa-
tions (p < 0.05), confirming previous MR findings of an
increased risk of CAD, within the UK Biobank population
(Figure 3, Table S16). Our results also provide genetic evi-
dence for associations of shorter LTL with increased risk
of rheumatoid arthritis, aortic valve stenosis, chronic
obstructive pulmonary disease, and heart failure, all of
which have previously been observationally associated
with shorter LTL.89–92 We also ran the MR analyses using
only the genome-wide significant variants (Figure S4),
and we did not lose any Bonferroni-significant hits, with
only small differences in those diseases that are nominally
associated. In our sensitivity analyses, effect estimates were
consistent across MR methods. The MR-Steigers analysis
indicated that the direction of the relationship is that TLThe Ameriinfluences disease risk. This analysis also indicated that
this direction was estimated correctly for the majority of
diseases (Table S16).
We next sought to explore human diseases and traits
that share common genetic etiologies with LTL. We did
this by performing LD score regression analyses to test
for genetic correlations between TL and 320 curated traits
and diseases (Table S17) within LD Hub.15,16 In compari-
son to the MR approach, these analyses utilize genome-
wide genetic information rather than selected SNPs
with the most significant associations. In agreement with
our MR analyses, TL was negatively correlated with CAD
(r ¼ 0.17, p ¼ 0.01, Table S17). Dyslipidaemia risk factors
for CAD also showed concordant associations with shorter
TL, including higher LDL and total cholesterol and lower
HDL cholesterol (Table S17). These results are suggestive
of a shared genetic architecture underlying TL, CAD, and
CAD risk factors. However, these results would not survive
correction for multiple testing.
We also examined individual locus-driven genetic
correlations between TL and a variety of human pheno-
types and diseases by using PhenoScanner69 to query
52 FDR sentinel variants and their closely related SNPs
in LD (r2 S 0.8) against publicly available GWAS data-
bases. While some morbidities showed specific correla-
tions to a single locus, others showed correlations to a
broader spectrum of loci. For example, self-reported
hypothyroidism or myxoedema exhibited a strong asso-
ciation particularly at the TERT locus, which was also
exclusively responsible for several subtypes of ovarian
cancers (Table S18). In contrast, blood cell traits and he-
matological diseases were implicated with a wider range
of loci, including TERC, TERT, SENP7, ATM, BBOF1, and
MROH8; this result is similar to those for the respiratory
function and lung cancers that also involved multiple
TL loci (Table S18).Discussion
We identify 20 lead variants at a level of genome-wide
significance and a further 32 at FDR < 0.05. Within estab-
lished loci, we report a second, independent, association
signal within the TERT locus and redefine the RTEL1 locus
into three independent signals. By applying a range
of in silico tools that integrate multiple lines of evidence,
we were able to pinpoint likely influenced genes for
the majority of independent lead variants (34 of 52),
several of which represent key telomere-regulating path-
ways (including components of the telomerase complex,
the telomere-binding SHELTERIN and CST complexes,
and the DNA damage response [DDR] pathway).
Telomeres function to prevent the 30 single-stranded
overhang at the end of the chromosome from being de-
tected as a double-stranded DNA break. This is achieved
through binding of the SHELTERIN complex (TERF1,
TERF2, TERF2IP, TINF2, ACD, and POT1), which acts tocan Journal of Human Genetics 106, 389–404, March 5, 2020 397
Figure 3. Mendelian Randomization Results for the Effect of Shorter LTL on the Risk of 122 Diseases in the UK Biobank
Data shown are odds ratios and 95% confidence intervals for a 1 standard deviation shorter LTL. Diseases are classified into groups, as
indicated by the boxing, and sorted alphabetically within disease group. Nominally significant (p < 0.05) associations estimated via in-
verse-variance-weighted Mendelian randomization are shown in green for a reduction in risk and purple for an increase in risk due to
shorter LTL. O indicates nominal (p < 0.05) evidence of pleiotropy estimated by MR-Eggers intercept. Full results are also shown in Table
S16 along with the full MR sensitivity analysis.block activation of DDR pathways via severalmechanisms.3
SHELTERIN also binds a number of accessory factors that
facilitate processing and replication of the telomere,
including the DNA helicase RTEL1.3 SHELTERIN also inter-
acts with the CST complex that regulates telomerase access
to the telomeric DNA (Figure 1C).3 The associated loci
contain two of the SHELTERIN components (TERF2 and398 The American Journal of Human Genetics 106, 389–404, MarchPOT1), a regulator of TERF1, CSNK2B (PRRC2A locus),82
the helicase RTEL1, and the CST component STN1.
Although telomere-binding proteins and structure aim
to inhibit activation of DDR pathways, there is also evi-
dence of a paradoxical involvement of a number of DDR
factors in TL maintenance; these factors include both of
the prioritized genes, ATM and PARP1.73,93 TERF2 inhibits5, 2020
ATM activation and the classical non-homologous end
joining (c-NHEJ) at telomeres, thus preventing synapsis
of chromosome ends (Figure 1A).94 However, ATM activa-
tion is required for telomere elongation, potentially by
regulating access of telomerase to the telomere end
through ATM-mediated phosphorylation of TERF1.93 It is
possible that other DDR regulators can impact TL mainte-
nance by regulating telomeric chromatin states, T-loop
dynamics, and single-stranded telomere overhang process-
ing.79 Other prioritised genes (SENP7 and RFWD3) also
function within DDR pathways; this suggests a plausible
mechanism through which they may influence LTL.
The telomerase enzyme is capable of extending telo-
meres and/or compensating sequence loss due to the end
replication problem in stem and reproductive cells.4 Asso-
ciated loci include genes encoding the core telomerase
components TERT and TERC along with the chaperone
protein NAF1. NAF1 is required for TERC accumulation
and its incorporation into the telomerase complex.95 After
transcription, TERC undergoes complex 30 processing to
produce the mature 451bp template.96 This involves com-
ponents of the RNA exosome complex, PARN (MIM:
604212) and TENT4B (MIM: 605540), among others; this
process is not fully understood.97 In addition to variants
within regions containing TERT, TERC, and NAF1, a prior-
itiszed gene from another locus (MPHOSPH6) is a compo-
nent of the RNA exosome.98
Comparing our findings to those reported in a non-Euro-
pean study,70 we find support for our most significantly
associated loci. For many of our FDR < 0.05 loci, we were
unable to look for support from this study because our
sentinel variants were either monoallelic or rare (MAF <
0.01) in the CHS population. Different LD structures in re-
gions such as RTEL1, coupled with the reported absence of
some of the variants in other ancestral populations, sug-
gest that some of our reported variants may specific to Eu-
ropeans. Adding additional support for the existence of
population-specific rare variants regulating LTL is the dis-
covery of two loci in the Singaporean Chinese study that
are monoallelic in Europeans.70 Because both of these
replicate within CHS subjects and are located within re-
gions containing telomere-related genes, they are unlikely
to be false positive findings. Future large-scale trans-ethnic
meta-analyses will be critical in determining shared causal
variants from population-specific rare variants. This is of
key importance to downstream analyses using genetically
determined LTL to investigate disease risk in different pop-
ulations. However, the current lack of large-scale data on
LTL in non-European cohorts is limiting.
Utilizing the prioritized gene list as well as the closest
genes to the sentinel variants, we showed a number of
pathways to be enriched for telomere-associated loci. Of
note, we observed significant overrepresentation of genes
in several nucleotide metabolism pathways (Table S15,
Figure 2B). Key genes were highlighted by this function
in both the biosynthesis (TYMS, TK1, and DCK) and catab-
olism (SAMHD1) of dNTPs. Biosynthesis of dNTPs occursThe Amerivia two routes: de-novo synthesis and the nucleotide
salvage pathway. Thymidine kinase (TK1) and deoxycyti-
dine kinase (DCK) are the rate-limiting enzymes that cata-
lyze the first step of the salvage pathway of nucleotide
biosynthesis, converting deoxynucleosides to their mono-
phosphate forms (dNMPs) before other enzymes facilitate
further phosphorylation into deoxynucleodie dipho-
phates (dNDPs) and dNTPs (Figure 2B).85 Thymidylate syn-
thetase (TYMS) is considered to be a component of the de
novo pathway, and is the key regulator of dTMP biosyn-
thesis, converting deoxyuridine monophosphate (dUMP)
to dTMP.85 However, because the dUMP substrates can be
derived from either de novo synthesis or deamination of de-
oxycytidine monophosphate (dCMP) produced from the
salvage pathway, it could be considered to function within
both pathways (Figure 2B).85 Besides controlling biosyn-
thetic pathways, the equilibrium of cellular dNTP levels
is also achieved by regulating degradation of dNTPs, a
key regulator of which is SAMHD1. It catalyzes the hydro-
lysis of dNTPs to deoxynucleosides and triphosphates,
thereby preventing the accumulation of excess dNTPs
(Figure 2B).81 Although the finely tuned dNTP supply sys-
tem inhibits incorrect insertions of bases into DNA synthe-
sis, potential errors are monitored by the product of
another prioritized gene, the base excision repair enzyme,
SMUG1, which removes uracil and oxidized derivatives
from DNA molecules.84
A balanced cellular pool of dNTPs is required for DNA
replication and repair and for maintaining proliferative
capacity and genome stability. Low levels of dNTPs can
induce replication stress, subsequently leading to increased
mutation rates.99 A surplus of dNTPs, on the other hand, re-
duces replication fidelity, thus also causing higher levels of
spontaneous mutagenesis.100 A dynamic balance between
biosynthesis and catabolism is required to maintain an
equilibrium. Because maintaining the balance of the intra-
cellular dNTP pool is also fundamental to other pathways
that are implicated in telomere homeostasis, including
cellular proliferation and DNA repair, disruption of dNTP
homeostasis may trigger a sequence of cellular events that
interplay synergistically, leading to abnormalities of TL
and genome instability.
By clustering our prioritized genes via their functional
connections, we highlighted a number of pathways that
were enriched for TL regulation, which included DNA
replication, transcription, and repair; cell cycle regulation;
immune response; and intracellular trafficking. However,
we noted that because the gene prioritization was based
on integration of bioinformatic evidence from a number
of publicly available databases, which also laid the founda-
tion for establishing the pathways used in the enrichment
analyses, this approach may suffer from self-fulfilling cir-
cular arguments.
While supporting previous evidence linking shorter TL
to an increased risk of CAD and lower risk of several can-
cers, we demonstrated additional associations between
TL and thyroid disease, thyroid cancer, lymphoma, andcan Journal of Human Genetics 106, 389–404, March 5, 2020 399
several non-malignant neoplasms. Shorter TL was protec-
tive against all of these proliferative disorders, potentially
through limiting cell proliferative capacity, which in turn
reduces the occurrence of potential oncogenic mutations
that can occur during DNA replication. Furthermore, we
also provide evidence suggesting that shorter TL is poten-
tially causally associated with increased risk of several car-
diovascular, inflammatory, and respiratory disorders that
have previously been linked to TL in observational studies.
Our findings linking nucleotide metabolism to TL regula-
tion could in part explain the link between TL and cancer
and proliferative disorders. This would suggest that cells
with longer TL have higher dNTP levels that lead to higher
proliferation rates and reduced DNA replication fidelity
leading to higher mutation rates.
In summary, our findings substantially expand current
knowledge on the genetic determinants of LTL, and they
elucidate genes and pathways that regulate telomere ho-
meostasis and their potential impact on human diseases
and cancer development.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2020.02.006.Acknowledgments
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